Evommune, Inc.
EVMNHealthcare|Biotechnology|US
$6.65
+0.28 (+4.40%)
Tangible Book / Share
$7.68
Cash / Share
$5.56
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07616128 Study of EVO756 in Adults With Migraine | Migraine | P2 | Recruiting | 330 | RCT, Double-blind | EVO756, Dose 1, EVO756, Dose 2, Placebo |
| NCT06645821 Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% | Hidradenitis Suppurativa (HS) | Early P1 | Recruiting | 15 | Open-label | EVO101 |
| NCT06873516 Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) | Chronic Spontaneous Urticaria | P2 | Completed | 182 | RCT, Double-blind | EVO756, EVO756, EVO756, Placebo control |
| NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis | Atopic Dermatitis | P2 | Completed | 121 | RCT, Double-blind | EVO756, EVO756, EVO756, Placebo control |
| NCT06723405 Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis | Atopic Dermatitis (AD), Eczema | P2 | Completed | 71 | RCT, Double-blind | EVO301, Placebo |
| NCT05579899 Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis | Atopic Dermatitis Eczema | P2 | Completed | 119 | RCT, Double-blind | EVO101 |
| NCT06603220 A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria | Chronic Inducible Urticaria | P2 | Completed | 30 | Open-label | Oral EVO756 300 mg QD, Oral EVO756 50 mg BID |